Imagen de Portada

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Carolin V. Schneider, Kai Markus Schneider, Rohit Loomba
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
por: Carolin V. Schneider, et al.
Publicado: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
por: Samer Gawrieh, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
por: Manya Prasad, et al.
Publicado: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
por: Nobuharu Tamaki, et al.
Publicado: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
por: Federica Tavaglione, et al.
Publicado: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
por: Maral Amangurbanova, et al.
Publicado: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
por: Nabil Noureddin, et al.
Publicado: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
por: Richie Manikat, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
por: Donghee Kim, et al.
Publicado: (2025)

Editorial: Quantity is important! Authors' reply
por: Marika Rudler, et al.
Publicado: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
por: Eunice X. X. Tan, et al.
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
por: Mikkel Malham, et al.
Publicado: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
por: Richie Manikat, et al.
Publicado: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
por: Kyuwon Kim, et al.
Publicado: (2024)

A Message From the Editors
por: Colin W. Howden, et al.
Publicado: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
por: Stephanie A. Vuijk, et al.
Publicado: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
por: Benedikt Silvester Hofer, et al.
Publicado: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
por: R. M. Mathias, et al.
Publicado: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
por: Nina Løn, et al.
Publicado: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
por: María Hernández‐Pérez, et al.
Publicado: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
por: Victoria T. Kronsten, et al.
Publicado: (2024)

Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply
por: Matthew J. Armstrong, et al.
Publicado: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
por: Maria Gabriela Fernandes Dezan, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
por: Dipesh H. Vasant, et al.
Publicado: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
por: Linda Henry, et al.
Publicado: (2024)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
por: Selena Z. Kuo, et al.
Publicado: (2025)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
por: Yewan Park, et al.
Publicado: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
por: Mohamad Jamalinia, et al.
Publicado: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
por: Lana Bridi, et al.
Publicado: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
por: Hsin‐Che Lin, et al.
Publicado: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
por: Marta Paula Pereira Coelho, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
por: Tomohiro Fukuda, et al.
Publicado: (2024)